{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T05:53:35.843622+00:00","company":{"ticker":"RLYB","cik":1739410,"company_name":"Rallybio Corp"},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"81da4d6c8358f31e520528be03ecbcd68e972f98","cik":1739410,"ticker":"RLYB","company_name":"Rallybio Corp","filed_at":"2026-05-04T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Agreement and Plan of Merger and Reorganization","agreement_type":"merger","counterparty":"Candid Therapeutics, Inc.","effective_date":"2026-05-03","item_codes_triggered":["1.02"],"value_text":"$50,000,000 Parent Termination Fee"},"claim":"Rallybio Corp terminated Agreement and Plan of Merger and Reorganization with Candid Therapeutics, Inc. valued at $50,000,000 Parent Termination Fee (effective 2026-05-03).","evidence_excerpt":"On May 3, 2026, Candid terminated the Merger Agreement concurrently with entering into a Permitted Alternative Agreement (as defined in the Merger Agreement) with UCB S.A. (“ UCB ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-202601","anchor_url":"https://secwatch.observer/filing/0001193125-26-202601#claim-81da4d6c8358f31e520528be03ecbcd68e972f98","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1739410/000119312526202601/0001193125-26-202601-index.htm"},{"fact_type":"material_agreement","fact_key":"69184b6378a2d470105f3ff76aca2c0967e0addc","cik":1739410,"ticker":"RLYB","company_name":"Rallybio Corp","filed_at":"2026-03-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger and Reorganization","agreement_type":"merger","counterparty":"Candid Therapeutics, Inc.","effective_date":"2026-03-01","item_codes_triggered":["1.01"],"value_text":null},"claim":"Rallybio Corp entered into Agreement and Plan of Merger and Reorganization with Candid Therapeutics, Inc. (effective 2026-03-01).","evidence_excerpt":"On March 1, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc., a Delaware corporation (“ Candid ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-084444","anchor_url":"https://secwatch.observer/filing/0001193125-26-084444#claim-69184b6378a2d470105f3ff76aca2c0967e0addc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/0001193125-26-084444-index.htm"},{"fact_type":"governance_change","fact_key":"20ed413b5f52e444de4e07934548e5271e33097c","cik":1739410,"ticker":"RLYB","company_name":"Rallybio Corp","filed_at":"2026-01-29T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-02-06","item_codes_triggered":["5.03"],"summary_text":"Effected a 1-for-8 reverse stock split of common stock via Certificate of Amendment to the Amended and Restated Certificate of Incorporation."},"claim":"Rallybio Corp: Effected a 1-for-8 reverse stock split of common stock via Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2026-02-06).","evidence_excerpt":"On January 26, 2026, Rallybio Corporation (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 (the “Common Stock”) at a ratio of 1-for-8 (the “Reverse Stock Split”). Pursuant to the Certificate of Amendment, the Reverse Stock Split will be effective at 12:01 a.m., Eastern Time, on February 6, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001739410-26-000010","anchor_url":"https://secwatch.observer/filing/0001739410-26-000010#claim-20ed413b5f52e444de4e07934548e5271e33097c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941026000010/0001739410-26-000010-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"3784bd669b9d6f4cbe0964aa7dc24531dbf02213","cik":1739410,"ticker":"RLYB","company_name":"Rallybio Corp","filed_at":"2025-08-29T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-02-23","deficiency_type":"minimum_bid_price","delisting_effective_date":"2025-08-29","exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-02-24","notice_type":"noncompliance_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":[],"rules_cited_in_text":false},"claim":"Rallybio Corp received a nasdaq noncompliance notice notice regarding minimum bid price.","evidence_excerpt":"February 24, 2025, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the prior 30 consecutive business days (the “Notice”), as required for continued listing on the Nasdaq. Pursuant to Nasdaq’s Listing Rules, the Company had until August 25, 2025 (the “Initial Compliance Date”) to regain compliance with the minimum closing bid price requirement. As of the Initial Complian","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-192749","anchor_url":"https://secwatch.observer/filing/0001193125-25-192749#claim-3784bd669b9d6f4cbe0964aa7dc24531dbf02213","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1739410/000119312525192749/0001193125-25-192749-index.htm"},{"fact_type":"ma_transaction","fact_key":"d01edd38e01377ddaa02fbe3d2a00c1052eeb19d","cik":1739410,"ticker":"RLYB","company_name":"Rallybio Corp","filed_at":"2025-07-08T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2025-07-08","consideration_text":null,"counterparty":"Recursion Pharmaceuticals, Inc.","effective_date":"2025-07-08","item_codes_triggered":["2.01"]},"claim":"Rallybio Corp completed a disposition involving Recursion Pharmaceuticals, Inc. (closed 2025-07-08).","evidence_excerpt":"On July 8, 2025, Rallybio Corporation (“Rallybio”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Recursion Pharmaceuticals, Inc., (“Recursion”), Exscientia Ventures I, Inc., an indirect wholly-owned subsidiary of Recursion (“Buyer”) and Rallybio IPB, LLC, a wholly-owned subsidiary of Rallybio (“Seller”), pursuant to which Buyer purchased 50% of the issued and outstanding membership interests (the “Membership Interests”) of RE Ventures I, LLC (the “ENPP1 JV”) from Seller in exchange for cash and the issuance of shares (“Shares”) of Class A Common Stock of Recursion (the “Sale”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001739410-25-000100","anchor_url":"https://secwatch.observer/filing/0001739410-25-000100#claim-d01edd38e01377ddaa02fbe3d2a00c1052eeb19d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000100/0001739410-25-000100-index.htm"},{"fact_type":"executive_change","fact_key":"d31ac73973","cik":1739410,"ticker":"RLYB","company_name":"Rallybio Corp","filed_at":"2024-09-17T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-10-31","interim":false,"role":"Member of the Board and Chair of the Nominating and Corporate Governance Committee","role_category":"director","successor_name":null,"successor_named":false},"claim":"Kush Parmar resigned as Member of the Board and Chair of the Nominating and Corporate Governance Committee at Rallybio Corp.","evidence_excerpt":"On September 16, 2024, Dr. Kush Parmar informed the Board of Directors (the Board) of Rallybio Corporation (Rallybio) that he intends to resign as a member of the Board and as Chair of the Nominating and Corporate Governance Committee of the Board effective October 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001739410-24-000121","anchor_url":"https://secwatch.observer/filing/0001739410-24-000121#claim-d31ac73973","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000121/0001739410-24-000121-index.htm"},{"fact_type":"executive_change","fact_key":"8e542c877d","cik":1739410,"ticker":"RLYB","company_name":"Rallybio Corp","filed_at":"2024-07-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-12-31","interim":false,"role":"Executive Chairman","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Martin Mackay resigned as Executive Chairman at Rallybio Corp.","evidence_excerpt":"On July 23, 2024, Martin Mackay, Ph.D., informed the Board of Directors (the Board) of Rallybio Corporation (Rallybio) that he will resign his Executive Chairman role and his employment with Rallybio, effective December 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001739410-24-000105","anchor_url":"https://secwatch.observer/filing/0001739410-24-000105#claim-8e542c877d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000105/0001739410-24-000105-index.htm"},{"fact_type":"earnings_release","fact_key":"2869a78a5fff0e942dd40121ddfadb137b6efbc7","cik":1739410,"ticker":"RLYB","company_name":"Rallybio Corp","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Rallybio Corp reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Rallybio Corporation issued a press release announcing its financial results for the quarter ended March 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001739410-24-000053","anchor_url":"https://secwatch.observer/filing/0001739410-24-000053#claim-2869a78a5fff0e942dd40121ddfadb137b6efbc7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000053/0001739410-24-000053-index.htm"},{"fact_type":"material_agreement","fact_key":"f589650dc23eabdf143ff776cb5778350cb58903","cik":1739410,"ticker":"RLYB","company_name":"Rallybio Corp","filed_at":"2024-04-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Johnson & Johnson Innovation – JJDC, Inc.","effective_date":"2024-04-10","item_codes_triggered":["1.01"],"value_text":"approximately $6.6 million"},"claim":"Rallybio Corp entered into Securities Purchase Agreement with Johnson & Johnson Innovation – JJDC, Inc. valued at approximately $6.6 million (effective 2024-04-10).","evidence_excerpt":"On April 10, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Johnson & Johnson Innovation – JJDC, Inc., a Delaware corporation (the “Purchaser”), pursuant to which the Company sold to the Purchaser, in an unregistered offering (the “Offering”), shares of common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001739410-24-000040","anchor_url":"https://secwatch.observer/filing/0001739410-24-000040#claim-f589650dc23eabdf143ff776cb5778350cb58903","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/0001739410-24-000040-index.htm"},{"fact_type":"material_agreement","fact_key":"150bc7a13097ea0ddbea78c2335ec5018af85f3e","cik":1739410,"ticker":"RLYB","company_name":"Rallybio Corp","filed_at":"2024-04-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Collaboration Agreement","agreement_type":"collaboration","counterparty":"Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc.","effective_date":"2024-04-09","item_codes_triggered":["1.01"],"value_text":"$0.5 million"},"claim":"Rallybio Corp entered into Collaboration Agreement with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. valued at $0.5 million (effective 2024-04-09).","evidence_excerpt":"On April 9, 2024, Rallybio Corporation (the “Company”), through its subsidiary Rallybio IPA, LLC, entered into a collaboration agreement (the “Collaboration Agreement”) with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. (“J&J”),","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001739410-24-000040","anchor_url":"https://secwatch.observer/filing/0001739410-24-000040#claim-150bc7a13097ea0ddbea78c2335ec5018af85f3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/0001739410-24-000040-index.htm"}]}